Advanced cross-linked HA filler with 24mg/ml medical-grade hyaluronic acid and 3mg/ml lidocaine. Utilizing UPHEC purification technology (patented by Newmedic Co.) achieving ≤0.05 EU/ml endotoxin levels, clinically proven to maintain volumizing effects for 12-18 months in 89% of cases (2023 KDA clinical trial).

Clinical Protocol:
1. For subdermal injection (2-6mm depth)
2. 0.2-0.5ml per nasolabial fold
3. 27G ½” needle (0.4mm diameter)
4. Post-op cooling recommended

Packaging Specifications:
✓ 1.1ml sterile syringe
✓ 2×27G medical needles
✓ CE0482 certification
✓ Batch-tracked vial

Indications: Mid-to-deep dermal augmentation
Contraindications: Active inflammation sites
Storage: 2-25°C protected from light

*Clinical outcomes may vary depending on individual metabolism (15-22% variance observed). Certified practitioners must assess tissue compatibility prior to administration. Not for superficial injection.